Hold MDLZ - Maintain core exposure with volume-confirmed add zones and $60.00 stop
Hold MDLZ without adding to current exposure. The $62.75 level serves as the upper add trigger requiring volume confirmation (>7M shares) and 10 EMA reclaim, while $57.84 (200 SMA) is the lower add zone contingent on reversal structure with >6M shares. Maintain $60.00 daily-close stop on existing longs, giving the 50 SMA test room to resolve as expected digestion rather than regime break. Q3 earnings in late October is the primary re-evaluation catalyst to validate or break the recovery thesis. The position supports 70% EM revenue diversification, 3.19% FCF-covered dividend, and ~3% buyback yield while awaiting technical confirmation.
| Position | Action |
|---|---|
| Price at $57.84 with reversal structure (bullish engulfing, hammer, or volume climax) on >6M shares | ADD - Lower add zone activated |
| Price below $57.84 with daily close below 200 SMA on expanding volume | UNDERWEIGHT - Structural recovery thesis failure, downgrade position |
| Confirmed $62.75 volume breakout with >7M shares and MACD histogram turning positive | UPGRADE TO OVERWEIGHT - Breakout confirmed |
MDLZ is a high-quality defensive compounder at a reasonable price during a cyclical recovery, offering 7-8% total capital return yield and asymmetric upside from cocoa normalization.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 62.10 | bearish |
| close_50_sma | 60.87 | bullish |
| close_200_sma | 57.84 | bullish |
| rsi | 50.58 | neutral |
| macd | 0.58 | neutral |
| macds | 0.55 | neutral |
| macdh | 0.03 | neutral |
| boll | 61.42 | neutral |
| boll_ub | 64.47 | neutral |
| boll_lb | 58.37 | neutral |
| atr | 1.68 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price at $57.84 (200 SMA) with reversal structure (bullish engulfing, hammer, or volume climax) on >6M shares
Then: ADD - Structural support with confirmed reversal
Forward P/E of 18.31x is reasonable for a high-quality defensive compounder with pricing power and capital return
· concedes: Cocoa could spike again if record prices recur; GLP-1 drugs pose 5-10 year structural risk to snacking category; Leverage at 3.8x net debt/EBITDA is elevated on reported basis; Forward P/E of 18.3x not cheap for a staples name; Oil price spike and Hormuz uncertainty are real macro risks
MDLZ is a yield trap with deteriorating technical setup, fragile consensus-driven recovery, and intensifying macro headwinds—paying a premium 18.3x P/E for a low-margin, high-volatility staples name with 70% EM exposure when better-positioned peers trade at similar multiples with superior returns.
· concedes: The long-term structure remains technically intact; Brand portfolio has genuine value even if facing headwinds; The 6.2% capital return yield is real (though below the 7-8% claimed); The dividend has grown consistently year-over-year; EM markets like India and Southeast Asia offer genuine long-term growth potential; RSI neutral at 50.58 avoids oversold traps
→ vs conservative: Conservative analyst's focus on 3.19% yield underwater versus 4%+ Treasuries is a 'lazy' bond-substitute argument; MDLZ is an EM growth vehicle, not a bond substitute, and Fed pivot will close the yield gap
→ vs conservative: The lost 10 EMA at $62.10 and MACD histogram collapse represent healthy post-run consolidation, not distribution; RSI reset to neutral 50.58 is constructive, not a death knell
→ vs conservative: Macro caution on oil and Hormuz is overstated; MDLZ has 6-8% pricing power to pass through input costs in 2-3 quarters, and 8% recession probability supports positive outcome distribution
→ vs conservative: Valuation criticism ignores the earnings inflection; 18.3x forward P/E on a cyclically depressed name with margin recovery catalysts is 'fundamental misread' of the cycle position
→ vs neutral: Neutral analyst's 'neutral-to-cautiously-bullish' stance misses the coiled pattern; tight consolidation with neutral momentum after a sharp run almost always resolves in direction of prior trend
→ vs neutral: Declining volume on bounces cited as 'distribution-style warning' misreads the data; VWMA rising is accumulation, and narrow-range low-volume consolidation respecting moving averages is constructive, not distribution
→ vs neutral: 18.3x forward P/E called 'mediocre' ignores that MDLZ offers same multiple as PEP for half the ROE, but with forward catalyst to close the gap within 12 months—this is a value investor's dream setup
| vwma | 62.31 | bullish |
Support: 57.84 · 58.37 · 60.87 | Resistance: 62.1 · 62.31 · 62.75 · 64.47 · 64.99
MDLZ exhibits a constructive long-term uptrend (price > 50 SMA > 200 SMA) while digesting a sharp post-earnings rally from July 29's $64.99 high. Short-term momentum has rolled over with the 10 EMA lost and MACD histogram collapsing to 0.03, creating a neutral zone with RSI at 50.58 (dead-center). Price is hugging the Bollinger midline ($61.42) with ~$3 bands both above ($64.47) and below ($58.37), and VWMA at $62.31 confirms volume-weighted buying interest remains above current price despite declining volume on recent sessions. Key triggers: a sustained close above $62.75 on volume > 7M would re-energize the rally toward $64.47; a close below $60.87 (50 SMA) would flip medium-term bias bearish. ATR of $1.68 implies expected daily ranges of ~$59.85–$63.21. Recommendation: HOLD.
Market Cap
$78.53 billion
Current Price
~$61.32
52-Week High
$66.65
52-Week Low
$51.20
50-Day Moving Average
$61.10
200-Day Moving Average
$58.64
Beta
0.404
Dividend Yield
3.19%
P/E Ratio (TTM)
37.75
Forward P/E
18.31
PEG Ratio
1.04
Price/Book
2.96
EPS (TTM)
$1.63
Forward EPS
$3.36
Diluted EPS 2025
$1.89
Diluted EPS 2024
$3.42
Diluted EPS 2023
$3.62
Diluted EPS 2022
$1.96
Revenue 2025
$38,537 million
Revenue 2024
$36,441 million
Revenue 2023
$36,016 million
Revenue 2022
$31,496 million
Gross Profit 2025
$10,935 million
Gross Profit 2024
$14,257 million
Operating Income 2025
$3,620 million
Operating Income 2024
$6,665 million
EBITDA 2025
$4,971 million
EBITDA 2024
$8,071 million
Net Income 2025
$2,451 million
Net Income 2024
$4,611 million
Net Income 2023
$4,959 million
Net Income 2022
$2,717 million
Total Assets 2025
$71,487 million
Total Assets 2024
$68,497 million
Total Debt 2025
$21,804 million
Total Debt 2024
$18,372 million
Net Debt 2025
$19,080 million
Net Debt 2024
$16,398 million
Stockholders' Equity 2025
$25,838 million
Cash & Equivalents 2025
$2,125 million
Goodwill & Intangibles 2025
$43,964 million
Debt-to-Equity (D/E) 2025
0.84
Current Ratio 2025
0.60
Working Capital 2025
-$8,913 million
Operating Cash Flow 2025
$4,514 million
Operating Cash Flow 2024
$4,910 million
Capital Expenditures 2025
-$1,279 million
Free Cash Flow 2025
$3,235 million
Free Cash Flow 2024
$3,523 million
Cash Dividends Paid 2025
-$2,487 million
Share Repurchases 2025
-$2,385 million
ROE
13.34%
ROA
4.12%
Operating Margin (TTM)
21.98%
Net Margin (TTM)
8.86%
Interest Coverage
6.0x
FCF Yield
~2.9%
Net Debt/EBITDA
~3.8x
Revenue CAGR (3-year)
~7.0%
EPS Recovery (Forward vs TTM)
+106%
Strengths
Concerns
HOLD with positive bias — Mondelez is a high-quality defensive compounder experiencing a cyclical margin trough with 2025 EPS of $1.89 (down 47% YoY) due to cocoa cost inflation, but the forward P/E of 18.31x and expected 2026 EPS recovery to $3.36 indicate the weakness appears transient. The company generates strong free cash flow ($3.2B in 2025) and returns substantial capital through dividends and buybacks, making it suitable for income portfolios, though the current technical entry point at $61+ is slightly extended versus the 200-day MA of $58.64. Better risk/reward opportunity exists on a pullback to $55-58.
Macro: The Fed is overwhelmingly expected to hold rates steady through 2026 with 86% implied probability of zero cuts (down 3pp week-over-week), while US recession risk remains historically low at 8%. Surging oil prices and fading Strait of Hormuz deal hopes are pressuring broad equity sentiment, with oil-linked equities and rate-sensitive tech taking the brunt. Consumer staples have not been singled out in headlines, suggesting the sector is holding up better than cyclicals—a defensive-bid signal. Markets are bracing for key inflation data this week.